NASDAQ:EOLS Evolus (EOLS) Stock Forecast, Price & News $9.19 +0.04 (+0.44%) (As of 09/22/2023 ET) Add Compare Share Share Today's Range$9.14▼$9.2650-Day Range$7.21▼$10.2052-Week Range$6.51▼$11.49Volume233,859 shsAverage Volume356,700 shsMarket Capitalization$523.55 millionP/E RatioN/ADividend YieldN/APrice Target$21.40 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Evolus MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside132.9% Upside$21.40 Price TargetShort InterestBearish8.02% of Float Sold ShortDividend StrengthN/ASustainability-1.27Upright™ Environmental ScoreNews SentimentN/AInsider TradingAcquiring Shares$1.30 M Bought Last QuarterProj. Earnings GrowthGrowingFrom ($0.76) to ($0.51) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.18 out of 5 starsMedical Sector347th out of 965 stocksPharmaceutical Preparations Industry147th out of 455 stocks 3.5 Analyst's Opinion Consensus RatingEvolus has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $21.40, Evolus has a forecasted upside of 132.9% from its current price of $9.19.Amount of Analyst CoverageEvolus has only been the subject of 2 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted8.02% of the float of Evolus has been sold short.Short Interest Ratio / Days to CoverEvolus has a short interest ratio ("days to cover") of 5.1.Change versus previous monthShort interest in Evolus has recently decreased by 0.59%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldEvolus does not currently pay a dividend.Dividend GrowthEvolus does not have a long track record of dividend growth. Previous Next 3.5 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreEvolus has received a 40.61% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Private dermatologist's appointments", "Private internist's appointments", and "Botulinum toxin" products. See details.Environmental SustainabilityThe Environmental Impact score for Evolus is -1.27. Previous Next 1.3 News and Social Media Coverage News SentimentEvolus has a news sentiment score of 0.28. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.53 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Evolus this week, compared to 1 article on an average week.Search InterestOnly 2 people have searched for EOLS on MarketBeat in the last 30 days. This is a decrease of -88% compared to the previous 30 days.MarketBeat FollowsOnly 3 people have added Evolus to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Evolus insiders have bought 2,321.83% more of their company's stock than they have sold. Specifically, they have bought $1,296,505.00 in company stock and sold $53,534.00 in company stock.Percentage Held by InsidersOnly 5.40% of the stock of Evolus is held by insiders.Percentage Held by Institutions65.15% of the stock of Evolus is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Evolus are expected to grow in the coming year, from ($0.76) to ($0.51) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Evolus is -7.85, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Evolus is -7.85, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioEvolus has a P/B Ratio of 27.85. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Evolus (NASDAQ:EOLS) StockEvolus, Inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. It serves self-pay aesthetic healthcare market. Evolus, Inc. was incorporated in 2012 and is headquartered in Newport Beach, California.Read More EOLS Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart EOLS Stock News HeadlinesSeptember 19, 2023 | seekingalpha.comEvolus: Gaining Market ShareSeptember 15, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Qiagen (QGEN) and Evolus (EOLS)September 23, 2023 | Chaikin Analytics (Ad)This is the #1 Stock to Buy for the AI Tidal WaveMarc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.September 9, 2023 | finance.yahoo.comInsider Sell: CFO Sandra Beaver Sells 3,178 Shares of Evolus Inc (EOLS)September 7, 2023 | finance.yahoo.comEvolus, Inc. (NASDAQ:EOLS) is a favorite amongst institutional investors who own 56%August 31, 2023 | msn.comEvolus (EOLS) Price Target Increased by 7.28% to 20.66August 29, 2023 | finance.yahoo.comEvolus to Participate in September ConferencesAugust 23, 2023 | finance.yahoo.comEvolus Announces Inducement Grants for New Chief Marketing OfficerSeptember 23, 2023 | Chaikin Analytics (Ad)This is the #1 Stock to Buy for the AI Tidal WaveMarc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.August 21, 2023 | finance.yahoo.comEvolus Appoints Tomoko Yamagishi-Dressler as Chief Marketing OfficerAugust 18, 2023 | finance.yahoo.comInsider Spends US$1.3m Buying More Shares In EvolusAugust 16, 2023 | benzinga.comEvolus Director Trades $1.30M In Company StockAugust 7, 2023 | benzinga.comEquithy Discovers Increased Insider Trust Fuels Evolus Stock: A Golden Opportunity for Smart InvestorsAugust 7, 2023 | markets.businessinsider.comBarclays Reaffirms Their Hold Rating on Evolus (EOLS)August 3, 2023 | markets.businessinsider.comEvolus (EOLS) Receives a Buy from Mizuho SecuritiesAugust 2, 2023 | finance.yahoo.comEvolus Reports Second Quarter 2023 Results and Provides Business UpdateJuly 31, 2023 | msn.comEvolus raises FY 2023 guidance on record growth of new accountsJuly 29, 2023 | msn.comHC Wainwright & Co. Reiterates Evolus (EOLS) Buy RecommendationJuly 28, 2023 | markets.businessinsider.com5 Analysts Have This to Say About EvolusJuly 28, 2023 | finance.yahoo.comWhy Shares of Evolus Are Jumping ThursdayJuly 27, 2023 | finance.yahoo.comEvolus Raises Full-Year Revenue Guidance on Record Second Quarter 2023 RevenueJuly 27, 2023 | finance.yahoo.comEvolus to Participate in Canaccord Genuity’s 43rd Annual Growth ConferenceJuly 19, 2023 | finance.yahoo.comEvolus to Report Second Quarter 2023 Results and Provide Business UpdateJune 29, 2023 | seekingalpha.comEvolus: Botox Copy Cat In A Challenging Aesthetic MarketJune 29, 2023 | finance.yahoo.comEvolus Launches Nuceiva® (botulinum toxin type A) in ItalyJune 22, 2023 | stockhouse.comEvolus Announces Successful Completion of Phase 2 Study Evaluating "Extra-Strength" Dose of JeuveauJune 7, 2023 | msn.comMizuho Maintains Evolus (EOLS) Prior RecommendationSee More Headlines Receive EOLS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Evolus and its competitors with MarketBeat's FREE daily newsletter. Email Address EOLS Company Calendar Last Earnings8/02/2023Today9/22/2023Next Earnings (Estimated)11/14/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:EOLS CUSIPN/A CIK1570562 Webwww.evolus.com Phone(949) 284-4555FaxN/AEmployees215Year FoundedN/APrice Target and Rating Average Stock Price Forecast$21.40 High Stock Price Forecast$27.00 Low Stock Price Forecast$18.00 Forecasted Upside/Downside+132.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($1.17) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-74,410,000.00 Net Margins-39.36% Pretax Margin-39.29% Return on Equity-507.42% Return on Assets-34.58% Debt Debt-to-Equity Ratio10.37 Current Ratio2.33 Quick Ratio1.85 Sales & Book Value Annual Sales$148.62 million Price / Sales3.52 Cash FlowN/A Price / Cash FlowN/A Book Value$0.33 per share Price / Book27.85Miscellaneous Outstanding Shares56,970,000Free Float53,896,000Market Cap$523.55 million OptionableOptionable Beta1.60 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report Key ExecutivesMr. David Moatazedi (Age 45)Pres, CEO & Director Comp: $1.27MMs. Sandra Beaver (Age 45)Chief Financial Officer Comp: $372.23kDr. Rui Avelar C.CFP (Age 61)Dip.SportMed, M.D., Chief Medical Officer and Head of R&D Comp: $682.03kMr. David K. EricksonVP of Investor RelationsMr. Jeffrey J. PlumerGen. CounselMr. Kurt KnabVP of SalesMs. Tomoko Yamagishi-DresslerChief Marketing OfficerMs. Jessica NovakSr. VP of HRMore ExecutivesKey CompetitorsSavaraNASDAQ:SVRAOlema PharmaceuticalsNASDAQ:OLMAHarrow HealthNASDAQ:HROWAclaris TherapeuticsNASDAQ:ACRSWave Life SciencesNASDAQ:WVEView All CompetitorsInsiders & InstitutionsBarclays PLCSold 2,065 shares on 9/21/2023Ownership: 0.028%Sandra BeaverSold 3,178 sharesTotal: $30,826.60 ($9.70/share)California State Teachers Retirement SystemBought 5,706 shares on 8/21/2023Ownership: 0.090%Legato Capital Management LLCBought 27,208 shares on 8/18/2023Ownership: 0.180%Rui AvelarSold 2,211 sharesTotal: $22,706.97 ($10.27/share)View All Insider TransactionsView All Institutional Transactions EOLS Stock - Frequently Asked Questions Should I buy or sell Evolus stock right now? 4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Evolus in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" EOLS shares. View EOLS analyst ratings or view top-rated stocks. What is Evolus' stock price forecast for 2023? 4 Wall Street analysts have issued twelve-month price objectives for Evolus' shares. Their EOLS share price forecasts range from $18.00 to $27.00. On average, they predict the company's stock price to reach $21.40 in the next year. This suggests a possible upside of 132.9% from the stock's current price. View analysts price targets for EOLS or view top-rated stocks among Wall Street analysts. How have EOLS shares performed in 2023? Evolus' stock was trading at $7.51 at the beginning of 2023. Since then, EOLS shares have increased by 22.4% and is now trading at $9.19. View the best growth stocks for 2023 here. When is Evolus' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 14th 2023. View our EOLS earnings forecast. How were Evolus' earnings last quarter? Evolus, Inc. (NASDAQ:EOLS) announced its quarterly earnings results on Wednesday, August, 2nd. The company reported ($0.28) earnings per share for the quarter, missing analysts' consensus estimates of ($0.26) by $0.02. The company earned $49.35 million during the quarter, compared to analysts' expectations of $46.12 million. Evolus had a negative trailing twelve-month return on equity of 507.42% and a negative net margin of 39.36%. What guidance has Evolus issued on next quarter's earnings? Evolus updated its FY 2023 earnings guidance on Thursday, July, 27th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $185.00 million-$195.00 million, compared to the consensus revenue estimate of $187.83 million. What is David Moatazedi's approval rating as Evolus' CEO? 1 employees have rated Evolus Chief Executive Officer David Moatazedi on Glassdoor.com. David Moatazedi has an approval rating of 100% among the company's employees. This puts David Moatazedi in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Evolus own? Based on aggregate information from My MarketBeat watchlists, some companies that other Evolus investors own include Celadon Group (CGI), ADMA Biologics (ADMA), Chesapeake Energy (CHKAQ), Matinas BioPharma (MTNB), Advanced Micro Devices (AMD), Dynavax Technologies (DVAX), Sorrento Therapeutics (SRNE), Aldeyra Therapeutics (ALDX), Organigram (OGI) and Bionano Genomics (BNGO). When did Evolus IPO? (EOLS) raised $65 million in an IPO on Thursday, February 8th 2018. The company issued 5,000,000 shares at $12.00-$14.00 per share. Cantor and Mizuho Securities served as the underwriters for the IPO and SunTrust Robinson Humphrey and JMP Securities were co-managers. What is Evolus' stock symbol? Evolus trades on the NASDAQ under the ticker symbol "EOLS." Who are Evolus' major shareholders? Evolus' stock is owned by many different retail and institutional investors. Top institutional investors include Stonepine Capital Management LLC (7.91%), BlackRock Inc. (5.26%), Great Point Partners LLC (4.27%), Schroder Investment Management Group (2.87%), Boothbay Fund Management LLC (2.29%) and Marshall Wace LLP (1.82%). Insiders that own company stock include Alphaeon 1 Llc, Crystal Muilenburg, David Moatazedi, David N Gill, Lauren P Silvernail, Medytox Inc, Robert Hayman, Rui Avelar, Sandra Beaver and Vikram Malik. View institutional ownership trends. How do I buy shares of Evolus? Shares of EOLS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Evolus' stock price today? One share of EOLS stock can currently be purchased for approximately $9.19. How much money does Evolus make? Evolus (NASDAQ:EOLS) has a market capitalization of $523.55 million and generates $148.62 million in revenue each year. The company earns $-74,410,000.00 in net income (profit) each year or ($1.17) on an earnings per share basis. How many employees does Evolus have? The company employs 215 workers across the globe. How can I contact Evolus? Evolus' mailing address is 520 Newport Center Dr. Suite 1200, Newport Beach CA, 92660. The official website for the company is www.evolus.com. The company can be reached via phone at (949) 284-4555 or via email at ir@evolus.com. This page (NASDAQ:EOLS) was last updated on 9/23/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Evolus, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.